These 6 Dividend Stocks Look Like Income Bargains. Their Payout Ratios Say Otherwise
Six stocks are flashing high yields that look like income bargains, but a closer look at their payout ratios tells a very different story about which ones can actually keep the checks coming.
A dividend screener flags every company whose payout ran ahead of earnings or cash flow in a given period. That flag is where the work starts. Pfizer (NYSE:PFE | PFE Price Prediction) yields about 6.02% at $28.55, yet its trailing GAAP earnings of $0.77 per share fall well short of its $1.72 annual dividend. Whether that matters depends on why the gap exists. A high yield is only as good as the company’s ability to keep paying it.
Run This Four-Step Test Before Trusting Any Yield
A dividend is unsustainable when the business can’t fund it from cash flow without borrowing or selling assets, year after year. Check in this order:
- Use the right earnings base. Strip out non-cash impairments and write-downs. EPS works for ordinary corporates; REITs need FFO/AFFO, MLPs distributable cash flow, BDCs net investment income.
- Compare full-year free cash flow to dividends paid. A single quarter can be misleading because of working capital timing.
- Look for a disclosed explanation. An acquisition, legal payment, or restructuring charge is a reason. Silence from management is information too.
- Check funding and repeat. Is debt rising to fill the gap? Has it happened before? Did the yield climb because the share price gave way?
Ford Motor (F): Explainable Loss, Cyclical Risk
Ford Motor (NYSE:F) pays $0.60 a year, a yield near 4.99% at $12.02. Trailing EPS is -1.88, which trips every screener.
The explanation is on the record. The second-quarter 2026 GAAP loss of $1.33B came from $4.2B in pre-tax special charges, including $3.6B tied to the BlueOval SK joint venture disposition. Adjusted EPS of $0.42 beat the $0.35 estimate, and Ford raised full-year adjusted free cash flow guidance to $6.0 to $7.0B, against roughly $2.35B in annual dividend cash. Steps one and two pass. Step four is shakier: debt-to-equity sits at 4.66, interest coverage at 2.02, Model e is expected to lose about $4.0B this fiscal year, and Ford’s payment record shows a gap after its 2020 payout. A downturn is the real threat.
3M (MMM): Passes the Test
3M (NYSE:MMM) yields just 1.93%, so it barely counts as an income name. Its shortfall happened in 2024, when the quarterly payout dropped from $1.51 to $0.70 after the Solventum spinoff. It has since risen to $0.78.
Adjusted EPS guidance of $8.80 to $8.95 dwarfs the $3.12 forward dividend, and free cash flow guidance of $4.7 to $4.9B compares with about $1.61B in payouts. The open question is litigation: shareholders’ equity fell to $3.0B against $31.9B in liabilities after PFAS and earplug settlements.
Dow (DOW): Already Reset, Now Covered
Dow (NYSE:DOW) halved its quarterly dividend from $0.70 to $0.35 in 2025. It yields about 4.96%, and trailing EPS of -1.84 still looks alarming.
Cash tells a better story. Second-quarter 2026 free cash flow reached $692M against $253M in dividends paid, helped by a 30% jump in polyethylene prices. That dependence is the caveat: shares are up 43.22% over one year but down 34.96% over five, and a cycle rollover would test the reset payout.
Pfizer (PFE): Credible Explanation, Tight Cash
Pfizer’s GAAP gap has a clear cause. The second-quarter 2026 loss of $248M reflected a $3.8B impairment after sigvotatug vedotin failed in Phase 3, plus $867M in legal charges. Adjusted EPS guidance of $2.80 to $3.00 puts the payout near 61% at the low end.
Step two is where coverage looks thin. Pfizer’s free cash flow yield of 5.60% trails its 6.03% dividend yield, and it plans no buybacks in 2026 to preserve cash for deleveraging. Generic competition, a COVID revenue forecast cut from $5B to $4B, and a CFO departure add pressure. Cost savings of $6.7B through 2029 are the path to a safer payout.
Clorox (CLX): Partial Explanation, Real Cash Gap
Clorox (NYSE:CLX) yields about 5.88% at $85, a dividend aristocrat that raised its quarterly payout to $1.25. The yield is largely price-driven: shares fell 25.9% over the past year.
Fiscal 2026 free cash flow of roughly $405M fell short of the roughly $601M dividend expenditure, and the GAAP payout ratio runs near 103%. Management points to the GOJO acquisition and a “value-seeking consumer.” Even so, liabilities rose 48.5% to $7.54B while equity fell to $252M. Fiscal 2027 adjusted EPS guidance of $5.70 to $6.00 must convert to cash.
Whirlpool (WHR): Trap Already Sprung
Whirlpool (NYSE:WHR) shows a trailing yield of 9.37%, and that figure is a mirage. The quarterly dividend fell from $1.75 to $0.90 in 2025, and no common dividend was declared in the second quarter of 2026.
No one-off explains it. Whirlpool posted an ongoing loss of $0.21 per share versus an expected $0.05 profit, revenue fell 6.8%, and it issued $2.0B in secured bonds to clear maturities. Shares are down 59.48% since the end of 2025. Every step of the test fails.
Why the Test Matters More Than the Yield
A one-time charge or acquisition can explain a single bad period. However, repeated shortfalls funded by debt usually can’t. When a dividend does get cut, the share price often drops with it, as Whirlpool shows. Yield alone isn’t a reason to buy, so run the four steps before you trust the payout (we listed seven warning signs that a big yield is about to be cut in a free dividend trap guide if you want a longer checklist).
Contact [email protected] for any questions or corrections.






